-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Benzinga·08/27/2026 13:45:24
Listen to the news
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.